Atopic dermatitis research record
15 treatments have a posted result against a comparison group. The exact treatment and comparison numbers are below.
The guide helps with care decisions. This page is the supporting trial record.
01
These treatments have at least one completed trial that posted a result against a comparison group — the only kind of result that can show the treatment itself made the difference. Each card is one trial against its own comparator, so cards can’t be compared head-to-head. Every result-posting study in the record was scanned, not just recent ones. A “vehicle” is the same cream or gel without the active ingredient — the fairest comparison for a topical.
80 of 100
Upadacitinib 30 mg once daily (n=285)
16 of 100
placebo (n=281)
63.4 more people per 100 reached at least 75% less eczema severity at week 16.
Outcome: Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 · NCT03569293 details · ClinicalTrials.gov record · Phase 3 · Industry-run
37 of 100
Ruxolitinib 0.75% Cream twice daily (n=134)
11 of 100
vehicle (no active) (n=65)
25.8 more people per 100 reached clear or almost-clear skin at week 8.
Serious adverse events in this trial: 0 of 159 on treatment vs 0 of 65 in the comparison group (submitted counts).
Outcome: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 · NCT04921969 details · ClinicalTrials.gov record · Phase 3 · Industry-run
40 of 100
Dupilumab every 2 weeks (n=67)
17 of 100
placebo (n=66)
23.6 more people per 100 reached clear or almost-clear skin at week 16.
Serious adverse events in this trial: 3 of 67 on treatment vs 1 of 66 in the comparison group (submitted counts).
Outcome: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 · NCT04417894 details · ClinicalTrials.gov record · Phase 3 · Industry-run
46 of 100
RPR Bari 4 mg (n=56)
38 of 100
RPR Placebo (n=32)
8.9 more people per 100 reached a meaningful drop in itch at week 16.
Outcome: RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved 4-Point Improvement in Itch NRS · NCT03334435 details · ClinicalTrials.gov record · Phase 3 · Industry-run
16 of 100
Tralokinumab 300 mg every 2 weeks (n=601)
7 of 100
placebo (n=197)
8.7 more people per 100 reached clear or almost-clear skin at week 16.
Outcome: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 · NCT03131648 details · ClinicalTrials.gov record · Phase 3 · Industry-run
22 of 100
Serlopitant 1 mg (n=161)
17 of 100
placebo (n=158)
5.9 more people per 100 reached the trial’s improvement bar at week 6 compared to baseline.
Serious adverse events in this trial: 1 of 160 on treatment vs 2 of 158 in the comparison group (submitted counts).
Outcome: WI-NRS 4-point Responder Rate at Week 6 · NCT02975206 details · ClinicalTrials.gov record · Phase 2 · Industry-run
5 more treatments have a comparative result — marked in the full treatment list below.
Before paying more for a newer option, check whether it beat the alternative in its own trial. In these primary outcomes, it didn’t:
22 registered eczema studies posted numeric results that this index maps to a treatment. Each has its own page showing exactly what was submitted, group by group.
Most trials compare against a placebo or vehicle. These posted outcomes compared one active treatment with another — the comparison that actually answers “which one?”:
Among the most-studied eczema treatments, these pairs have never even appeared together in a registered trial — so no public evidence says which one is better:
Regulatory status of the tracked treatments — whether the molecule studied in the trials above is available over the counter, as a generic, or brand-only. 4 of them have an OTC, generic, or biosimilar route.
| Treatment | Status | United States | Canada |
|---|---|---|---|
| montelukast (Singulair)Montelukast is approved for airway conditions; its appearance in eczema trials does not reflect an approved skin indication. | Generic prescription available | Generic prescription tablets and chewables, approved for asthma and allergic rhinitis; atopic dermatitis use is off-label. source | Generic prescription montelukast is available in Canada for the same airway indications. source |
| pimecrolimus (Elidel)Generic 1% creams contain the same molecule as the original Elidel brand. | Generic prescription available | Generic pimecrolimus 1% cream is available by prescription; the Elidel brand itself was discontinued by 2026. source | Elidel 1% cream is available by prescription in Canada. source |
| tacrolimus (Protopic)Topical tacrolimus ointment contains the same molecule used orally in transplant medicine, formulated for the skin. | Generic prescription available | Protopic 0.03% and 0.1% ointments are prescription-only and have FDA-approved generic equivalents (first generic ointment approved 2023). source | Protopic ointment is available by prescription in Canada. source |
| ustekinumab (Stelara, Wezlana, Selarsdi)Biosimilar versions of ustekinumab became available in the US in 2025 and are also approved in Canada. | Biosimilar available | Stelara plus multiple FDA-approved biosimilars (Wezlana, Selarsdi, Pyzchiva, Yesintek and others) launched during 2025; some are designated interchangeable. source | Health Canada-approved ustekinumab biosimilars are marketed alongside Stelara. source |
| abrocitinib (Cibinqo)Abrocitinib is available only as the brand Cibinqo. | Brand-only prescription | Cibinqo tablets (approved 2022) are prescription-only; no generic. source | Marketed as Cibinqo by prescription in Canada. source |
| apremilast (Otezla)Apremilast is a small-molecule tablet but currently has no marketed US generic. | Brand-only prescription | Otezla tablets are brand-only by prescription; no generic is currently marketed in the US. source | Otezla is available by prescription in Canada. source |
| baricitinib (Olumiant)Baricitinib is approved for atopic dermatitis in some countries (e.g., the EU) but not in the US. | Brand-only prescription | Olumiant is FDA-approved for other conditions (rheumatoid arthritis, alopecia areata, COVID-19); atopic dermatitis is not an FDA-approved indication. source | Marketed as Olumiant by prescription in Canada. source |
| crisaborole (Eucrisa)Unlike tacrolimus and pimecrolimus, crisaborole has no generic; all products are the Eucrisa brand. | Brand-only prescription | Eucrisa 2% ointment is prescription-only; no generic is available. source | Eucrisa has been available in Canada since 2018; prescription-only, no generic. source |
| roflumilast (Zoryve, Daliresp)The brand-only psoriasis cream and the generic COPD tablet contain the same molecule in different strengths and routes. | Brand-only prescription | Topical roflumilast (Zoryve cream and foam) is brand-only by prescription; oral roflumilast (Daliresp), approved for COPD, is generic. source | Zoryve cream (2023) and foam are approved by Health Canada; prescription-only. source |
| ruxolitinib (Opzelura, Jakafi, Jakavi)The same molecule is sold as the Opzelura skin cream and as oral tablets (Jakafi in the US, Jakavi in Canada) for different diseases. | Brand-only prescription | Opzelura 1.5% cream is prescription-only and brand-only; the same molecule is sold as oral tablets (Jakafi) for blood disorders. source | Opzelura cream authorized by Health Canada in October 2024 for atopic dermatitis and vitiligo; prescription-only. source |
| tapinarof (Vtama, Nduvra)Vtama (US) and Nduvra (Canada) contain the same tapinarof molecule under different brand names. | Brand-only prescription | Vtama 1% cream (psoriasis 2022, atopic dermatitis 2024) is brand-only by prescription. source | Approved by Health Canada in April 2025 under the brand Nduvra for plaque psoriasis; prescription-only. source |
| upadacitinib (Rinvoq)Upadacitinib is available only as the brand Rinvoq. | Brand-only prescription | Rinvoq extended-release tablets are prescription-only; no generic. source | Rinvoq is marketed in Canada by prescription, including for atopic dermatitis. source |
| dupilumab (Dupixent)Dupixent is the only dupilumab product in both markets; no biosimilar version exists yet. | Biologic — brand only | Dupixent injection is a prescription biologic; no biosimilar has been approved. source | Dupixent is marketed in Canada by prescription; no biosimilar. source |
| lebrikizumab (Ebglyss)Lebrikizumab is sold only as the brand Ebglyss in both markets. | Biologic — brand only | Ebglyss (approved by FDA in September 2024) is a prescription biologic; no biosimilar. source | Ebglyss authorized by Health Canada in 2024; prescription-only. source |
| nemolizumab (Nemluvio)Nemolizumab is sold only as the brand Nemluvio in both markets. | Biologic — brand only | Nemluvio approved in 2024 (prurigo nodularis in August, atopic dermatitis in December); prescription biologic, no biosimilar. source | Nemluvio authorized by Health Canada for atopic dermatitis and prurigo nodularis. source |
| secukinumab (Cosentyx)Secukinumab is available only as the brand Cosentyx in North America. | Biologic — brand only | Cosentyx is a prescription biologic; no biosimilar is marketed in the US. source | Cosentyx is marketed in Canada by prescription. source |
| tralokinumab (Adbry, Adtralza)Adbry (US) and Adtralza (Canada) are the same tralokinumab molecule under different brand names. | Biologic — brand only | Adbry injection is a prescription biologic; no biosimilar. source | Marketed as Adtralza in Canada by prescription. source |
| branebrutinibBranebrutinib is not commercially available anywhere. | Investigational — not approved | Investigational BTK inhibitor (BMS-986195) studied in phase 2 for atopic dermatitis; not approved in any market. source | not verified |
| difamilast (Moizerto)Difamilast is a topical PDE4 inhibitor in the same class as crisaborole but is only approved in Japan. | Investigational — not approved | Not approved in the US; approved in Japan as Moizerto ointment (2021). source | not verified |
Regulatory status only, verified 2026-08-20 with one source per claim — not pricing, coverage, or a recommendation. Status can change; check the linked source.
Search by brand or generic name, or browse the 60 most-studied terms. They are ordered by what the public record can show, not by benefit or safety.
At week 16, 40.3% of people in the Dupilumab Q2W group had the submitted improvement result (Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16), compared with 16.7% in the Matching Placebo group—23.6 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT04417894 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 12
At Baseline, Week 16, Percent Change From Baseline in Eczema Area and Severity Index (EASI) changed by -69.2% in the 250 mg Lebrikizumab (Q4W) group and -41.1% in the Placebo group—a difference 28.1 percentage points numerically larger in the selected group.
One submitted registry outcome, not a pooled estimate — from NCT03443024 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 16
At Week 16, 15.8% of people in the Tralokinumab 300 mg Q2W group had the submitted improvement result (Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16), compared with 7.1% in the Placebo Q2W group—8.7 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT03131648 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 16
At Week 16, 50% of people in the Baricitinib 2-mg Open-Label Addendum group had the submitted improvement result (Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)), compared with 59% in the Placebo/Baricitinib 2-mg group—9 fewer people per 100.
One submitted registry outcome, not a pooled estimate — from NCT03559270 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 16
At Baseline and Week 16, 79.7% of people in the Upadacitinib 30 mg QD group had the submitted improvement result (Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16), compared with 16.3% in the Placebo group—63.4 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT03569293 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 16
At Day 15, 50.9% of people in the Test group had the submitted improvement result (Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear [1])), compared with 45.6% in the Placebo group—5.3 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT03107611 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 2
At baseline to 12 weeks, Mean Change in Children's PROMIS Pediatric Itch Short-Form changed by -0.3 score on a scale in the Crisaborole group and -0.4 score on a scale in the Tacrolimus 0.03% group—a difference 0.1 score on a scale numerically smaller in the selected group.
One submitted registry outcome, not a pooled estimate — from NCT03645057 details · ClinicalTrials.gov record · Phase 3 · Other organization lead sponsor
At Baseline to Week 8, 36.6% of people in the VC Period: Ruxolitinib 0.75% Cream BID group had the submitted improvement result (VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8), compared with 10.8% in the VC Period: Vehicle Cream BID group—25.8 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT04921969 details · ClinicalTrials.gov record · Phase 3 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 4
At Baseline and 9 weeks, Mean Change in PADC (Caregivers Perception of Disease Control) changed by -0.8 units on a scale in the Treatment Arm group and -0.1 units on a scale in the Placebo Arm group—a difference 0.7 units on a scale numerically larger in the selected group.
One submitted registry outcome, not a pooled estimate — from NCT00557284 details · ClinicalTrials.gov record · Phase 4 · Other organization lead sponsor · vs placebo/vehicle · earliest favourable time point: week 9
At baseline to 12 weeks, Mean Change in Children's PROMIS Pediatric Itch Short-Form changed by -0.4 score on a scale in the Tacrolimus 0.03% group and -0.3 score on a scale in the Crisaborole group—a difference 0.1 score on a scale numerically larger in the selected group.
One submitted registry outcome, not a pooled estimate — from NCT03645057 details · ClinicalTrials.gov record · Phase 3 · Other organization lead sponsor · vs another active treatment · earliest favourable time point: week 12
At Baseline (Week 0) and at Week 16, 9.4% of people in the Benralizumab group had the submitted improvement result (Percentage of Participants With an Investigator Global Assessment (IGA) 0/1 and a Decrease in IGA of ≥2 Points at Week 16 Relative to Baseline), compared with 17.3% in the Placebo group—7.9 fewer people per 100.
One submitted registry outcome, not a pooled estimate — from NCT04605094 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle
At DB Period: Week 16, 3.3% of people in the DB Period: Etrasimod 2 mg group had the submitted improvement result (Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16), compared with 7.1% in the DB Period: Placebo group—3.8 fewer people per 100.
One submitted registry outcome, not a pooled estimate — from NCT05732454 details · ClinicalTrials.gov record · Phase 2 / Phase 3 · Industry lead sponsor · vs placebo/vehicle
At Week 6 compared to Baseline, 22.4% of people in the Serlopitant 1 mg group had the submitted improvement result (WI-NRS 4-point Responder Rate at Week 6), compared with 16.5% in the Placebo Oral Tablet group—5.9 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT02975206 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 6
At From baseline and 16 weeks, 0% of people in the Treatment 2 group had the submitted improvement result (Percentage of Participants Exhibiting a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 (Cleared) or 1 (Almost Cleared) AND a ≥ 2 Point Reduction From Baseline at Week 16), compared with 0% in the Placebo group—0 more people per 100.
One submitted registry outcome, not a pooled estimate — from NCT05014438 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle
At From baseline and 16 weeks, Mean Percentage Change From Baseline in EASI Score at Week 16 changed by -92.3% in the Treatment 4 group and -83.1% in the Placebo group—a difference 9.2 percentage points numerically larger in the selected group.
One submitted registry outcome, not a pooled estimate — from NCT05014438 details · ClinicalTrials.gov record · Phase 2 · Industry lead sponsor · vs placebo/vehicle · earliest favourable time point: week 16
02
Only 3 of 275 result-posting eczema studies reported participants’ separately measured skin type. The public record therefore rarely shows whether people with skin like yours were included.
Among 275 completed studies with posted results, this is how often each participant detail was reported.
03
Open the part you need. Every count remains tied to this condition and snapshot.
521 completed trials did not post numeric results to the registry as of 2026-09-11. A missing result does not mean the treatment failed; it means the public cannot check what happened.
Among studies that ended at least 12 months ago, 268 of 715 (37.5%) posted results.
69% were led by industry, usually the company selling the treatment. This is context about who asked the question, not proof that a result is wrong.
Lead sponsor class is not the same as all funding, and it is not a study-quality score.
Across 280 primary-outcome time points, the typical trial judged success around week 12. This record does not support a claim of visible results in days.
Median study duration: 17 months.
| Year | Study starts |
|---|---|
| 1998 | 1 |
| 1999 | 2 |
| 2000 | 2 |
| 2001 | 5 |
| 2002 | 6 |
| 2003 | 9 |
| 2004 | 28 |
| 2005 | 18 |
| 2006 | 13 |
| 2007 | 18 |
| 2008 | 22 |
| 2009 | 40 |
| 2010 | 28 |
| 2011 | 31 |
| 2012 | 27 |
| 2013 | 33 |
| 2014 | 35 |
| 2015 | 47 |
| 2016 | 47 |
| 2017 | 55 |
| 2018 | 83 |
| 2019 | 79 |
| 2020 | 68 |
| 2021 | 81 |
| 2022 | 98 |
| 2023 | 105 |
| 2024 | 93 |
| 2025 | 97 |
| 2026 | 82 |
| 2027 | 1 |
| 2030 | 1 |
| 2031 | 1 |
Study locations are not participant nationality or ancestry.
ClinicalTrials.gov data through · methodology v2.1.0 · snapshot 9a17314144e5…
Source: official ClinicalTrials.gov search · snapshot · result-mapping layer (v1.1.0, 2026-08-21) · field guide and citation.
As of 2026-09-11, 275 of 796 completed eczema trials registered on ClinicalTrials.gov have posted results, and 15 treatments have a posted result against a comparison group (Skinlogie Evidence Index, https://skinlogie.com/evidence-index/eczema).
Skinlogie’s derived figures are licensed CC BY 4.0 — reuse them with this attribution. Source records: ClinicalTrials.gov. Full dataset and citation format →